HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
Portfolio Pulse from
HOPE Therapeutics and NRx Pharmaceuticals will present a keynote on combined interventional treatment for suicidal depression and PTSD at the Neuroscience Innovation Forum. NRx has filed an NDA for NRX-100, and HOPE plans acquisitions to expand its psychiatry clinics.
January 07, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals is set to present at a major forum and has filed an NDA for NRX-100, a treatment for suicidal depression. HOPE Therapeutics, a subsidiary, plans significant acquisitions to expand its clinic network.
The presentation at a major forum and the NDA filing for NRX-100 are positive developments for NRx Pharmaceuticals, indicating progress in their product pipeline. Additionally, HOPE's planned acquisitions suggest growth potential, likely boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90